Cate Lockhart, PharmD, PhD

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.